Objective: To evaluate the intervention effect of sacral neuromodulation (SNM) in the treatment of lower urinary tract dysfunction after spinal cord injury (SCI). Methods: We selected relevant studies published between January 1, 1971 and November 15, 2018 by searching the PubMed, EMBASE, Cochrane databases. The outcome was assessed as follows: patients who had at least 50% improvement in bladder diary variables (number of leakages, pad use, number of voids, number of catheterizations, and so on). All analyses were performed with R software (version 3.5.1). We used Cochran’s Q test and I2 statistics to evaluate the heterogeneity. Results: A total of 8 articles met all inclusion criteria for the systematic review. According to the Oxford Centre for Evidence-Based Medicine hierarchy, the evidence levels ranged from 2b to 4. During the test phase of SNM, we considered 108 patients. During the test phase, the merged success rate was 45% (95% CI 36–55%, p = 0.23, I2 = 31%). Overall, 99 patients were considered during the permanent implantation phase of SNM; the mean follow-up time ranged from 8.4 to 61.3 months, and the merged success rate of the permanent SNM phase was 75% (95% CI 64–83%, p = 0.46, I2 = 0%). All the reported adverse events were resolved. Conclusions: Based on current evidence, the success rate of the test phase of SNM for LTUD in SCI patients was low, but in the permanent phase, the success rate of SNM was optimistic. In the future, well-designed randomized controlled trial with adequate sample sizes and power are necessary to validate the efficacy and safety of SNM.

Keywords:
Spinal cord injury, Sacral neuromodulation, Lower urinary tract dysfunction, Meta-analysis
1.
Samson G, Cardenas DD. Neurogenic bladder in spinal cord injury.
Phys Med Rehabil Clin N Am
. 2007 May;18(2):255–74.
2.
Gross C, Habli M, Lindsell C, South M. Sacral neuromodulation for nonobstructive urinary retention: a meta-analysis.
Female Pelvic Med Reconstr Surg
. 2010 Jul;16(4):249–53.
3.
Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Neurourol Urodyn
. 2015 Mar;34(3):224–30.
4.
Wang J, Chen Y, Chen J, Zhang G, Wu P. Sacral Neuromodulation for Refractory Bladder Pain Syndrome/Interstitial Cystitis: a Global Systematic Review and Meta-analysis.
Sci Rep
. 2017 Sep;7(1):11031.
5.
Chancellor MB, Chartier-Kastler EJ. Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions.
Neuromodulation
. 2000 Jan;3(1):16–26.
6.
Kurpad R, Kennelly MJ. The evaluation and management of refractory neurogenic overactive bladder.
Curr Urol Rep
. 2014 Oct;15(10):444.
7.
Lombardi G, Del Popolo G. Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms.
Spinal Cord
. 2009 Jun;47(6):486–91.
8.
Chen G, Liao L. Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease.
Spinal Cord
. 2015 Mar;53(3):204–208.
9.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
Syst Rev
. 2015 Jan;4(1):1.
10.
Mostafa A, Agur W, Abdel-All M, et al. Oxford Centre for Evidence-based Medicine–Levels of Evidence; 2009 (accessed May, 2016). Available from: http://www.cebm.net/oxford-centre-evidence-based-medicinelevels-evidencemarch-2009/.
11.
Wells GA, Shea B. O’Connell, et al. The Newcastle Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta analyses. Ottawa Hospital Research Institute (accessed May, 2016). Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
12.
Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D, et al. Assessing the quality of randomized trials: reliability of the Jadad scale.
Control Clin Trials
. 1999 Oct;20(5):448–52.
13.
Bemelmans BL, Mundy AR, Craggs MD. Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction.
Eur Urol
. 1999 Aug;36(2):81–91.
14.
van Balken MR, Vergunst H, Bemelmans BL. The use of electrical devices for the treatment of bladder dysfunction: a review of methods.
J Urol
. 2004 Sep;172(3):846–51.
15.
Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis.
Eur Urol
. 2010 Dec;58(6):865–74.
16.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.
BMJ
. 2003 Sep;327(7414):557–60.
17.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med
. 2002 Jun;21(11):1539–58.
18.
Hohenfellner M, Humke J, Hampel C, Dahms S, Matzel K, Roth S, et al. Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants.
Urology
. 2001 Dec;58(6):887–92.
19.
Spinelli M, Bertapelle P, Cappellano F, Zanollo A, Carone R, Catanzaro F, et al.; Gins Group. Chronic sacral neuromodulation in patients with lower urinary tract symptoms: results from a national register.
J Urol
. 2001 Aug;166(2):541–5.
20.
Spinelli M, Giardiello G, Gerber M, Arduini A, van den Hombergh U, Malaguti S. New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience.
J Urol
. 2003 Nov;170(5):1905–7.
21.
Lavano A, Volpentesta G, Aloisi M, Veltri C, Piragine G, Signorelli CD. Use of chronic sacral nerve stimulation in neurological voiding disorders.
J Neurosurg Sci
. 2004 Dec;48(4):157–9.
22.
Lombardi G, Musco S, Celso M, Ierardi A, Nelli F, Del Corso F, et al. Intravesical electrostimulation versus sacral neuromodulation for incomplete spinal cord patients suffering from neurogenic non-obstructive urinary retention.
Spinal Cord
. 2013 Jul;51(7):571–8.
23.
Ishigooka M, Suzuki Y, Hashimoto T, Sasagawa I, Nakada T, Handa Y. A new technique for sacral nerve stimulation: a percutaneous method for urinary incontinence caused by spinal cord injury.
Br J Urol
. 1998 Feb;81(2):315–8.
24.
Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, Chancellor MB, Richard F, Denys P. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia.
J Urol
. 2000 Nov;164(5):1476–80.
25.
Sievert KD, Amend B, Gakis G, Toomey P, Badke A, Kaps HP, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury.
Ann Neurol
. 2010 Jan;67(1):74–84.
26.
Lombardi G, Nelli F, Mencarini M, Del Popolo G. Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury.
Spinal Cord
. 2011 May;49(5):629–36.
27.
Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience.
Spinal Cord
. 2014 Mar;52(3):241–5.
28.
Jo HM, Kim HS, Cho YW, Ahn SH. Two-year outcome of percutaneous bipolar radiofrequency neurotomy of sacral nerves s2 and s3 in spinal cord injured patients with neurogenic detrusor overactivity: a randomized controlled feasibility study.
Pain Physician
. 2016 Jul;19(6):373–80.
29.
Niu HL, Ma YH, Zhang CJ. Comparison of OnabotulinumtoxinA versus sacral neuromodulation for refractory urinary urge incontinence: A systematic review and meta-analysis of randomized controlled trials. Int J Surg. 2018 Dec;60:141–148.
30.
Tutolo M, Ammirati E, Heesakkers J, Kessler TM, Peters KM, Rashid T, et al. Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature.
Eur Urol
. 2018 Jan;73(3):S0302-2838(17)30978-8.
31.
Wyndaele JJ. The management of neurogenic lower urinary tract dysfunction after spinal cord injury.
Nat Rev Urol
. 2016 Dec;13(12):705–14.
32.
Schurch B, Reilly I, Reitz A, Curt A. Electrophysiological recordings during the peripheral nerve evaluation (PNE) test in complete spinal cord injury patients.
World J Urol
. 2003 May;20(6):319–22.
33.
Chartier-Kastler E, Denys P. Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retention.
Neurourol Urodyn
. 2011 Jan;30(1):21–31.
34.
Chaabane W, Guillotreau J, Castel-Lacanal E, Abu-Anz S, De Boissezon X, Malavaud B, et al. Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study.
Neurourol Urodyn
. 2011 Apr;30(4):547–50.
35.
Minardi D, Muzzonigro G. Sacral neuromodulation in patients with multiple sclerosis.
World J Urol
. 2012 Feb;30(1):123–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.